This is
NOVAICOS Srls works on innovative solutions against bone erosion, with particular focus on osteoporosis, the aim is to deveope new compounds active in inhibiting bone resorption.
The problem
Despite existing therapies, the risk of tumor progression is still high, and innovative and highly effective novel treatments are required, with a better control over side effects.
The innovative solution
Novaicos develops new drugs able to inhibit tumor growth, metastasis dissemination, and osteolytic tumours. Novaicos carrying out experiments for the use of ICOS-Fc in nanoformulations for the treatment of tumor growth and related metastases. Novaicos addresses the thematic challenge of promoting innovation to improve cancer therapies and offering new solutions for the growing market of biological drugs. Biomaterials will allow the design of nanostructured and functionalized solutions to treat cancer. [continue]
The landscape
National expenditures for cancer care will increase by at least 27% in the last ten years because of aging and growing population. Novaicos’ drugs are effective in tumors decreasing burden and metastases, thus may be potentially used to treat also patients with osteolytic bone metastatic cancer. Therapeutic monoclonal antibodies are now approved in many countries as a valuable pharmacological strategy. Encouraging results obtained by this research project, together with the safety of the marketed drug delivery system employed, allow to foresee a good transferability to the human setting.
Development
Target
Development of new molecules active on bone resorption in different osteolytic diseases as osteoporosis and bone metastases. The first patented molecule is ICOS-Fc. ICOS-Fc is active in osteoporosis and osteopenia with possible development in the fields of autoimmunity and oncology.
Research for investors and industrial partners for the development of the research and clinical phase studies.
